Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.

Treadwell Therapeutics, US-based small molecule cancer therapy developer exploiting research from University Health Network, has secured more than $91m in a series B round co-led by pharmaceutical firm Sino Biopharmaceutical with investment adviser 3W Fund Management.

The round also featured venture creation firm Tio Bioventures, Prosperous Alliance, Alpha Win Capital, Fortune Ocean Growth Fund, private investor Adrian Cheng and unnamed others.

Spun out of Tio Bioventure’s drug discovery incubator, Treadwell is developing drugs that inhibit enzyme pathways to treat solid…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
email Linked in